Why peptides · why now
Compare Dallas providers by verifiable details.
Dallas-Fort Worth is one of the largest concierge medicine markets in the country. The corridor that runs from Park Cities through Preston Hollow up toward Plano and Frisco has been quietly building age-management and hormone-optimization protocols for two decades. Executive practices around Uptown, Knox-Henderson, and the Stemmons corridor see a steady stream of high-performing patients in their forties and fifties who are already running labs annually and treating the GH/IGF-1 axis as a domain worth understanding. What is changing now is the federal regulatory frame around growth-hormone-axis peptides, and the Dallas clinics that have been waiting on a clean legal lane are about to get one.
The short version: in 2023 the FDA placed several named peptides (BPC-157, KPV, TB-500, MOTs-C, and others) into Category 2 of the 503A bulk substances list, which restricts but does not prohibit compounding. On April 16, 2026 a Federal Register notice reopened the nominations process. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review the science and vote on whether those compounds move into Category 1 (clearly compoundable under 503A) or stay in Category 2. Whatever the committee decides, Dallas providers preparing for that meeting may be in a different position afterward.
Regulatory status depends on the exact product, intended use, prescriber, and dispensing pharmacy. FDA's July 2026 meeting agenda discusses specified nominated bulk substances; it is not a blanket authorization or an approval of a particular prescription. Read the FDA agenda, then ask the clinician and pharmacy to explain the current requirements for the exact product under discussion.